ALT, Chronic Hepatitis b
Conditions
Keywords
Hepatitis B, ALT
Brief summary
It remains unknown whether antiviral therapy is beneficial for chronic hepatitis B (CHB) with normal or mild ALT.The investigators aim to evaluate the antiviral indications combining liver biopsy and clinical parameters,and further clarify the response indexes of clinical results such as virological, serological, biochemical and histological responses from a retrospective observational cohort study on antiviral therapy in HBeAg positive and negative patients with different ALT levels,especially when ALT lower 2 times upper limit of normal (ULN).
Detailed description
It is estimated that 400 million people worldwide are chronically infected with hepatitis B virus (HBV).Chronic hepatitis B (CHB) often leads to serious health conditions including decompensated liver cirrhosis and hepatocellular carcinoma (HCC). Therefore, the goal of chronic hepatitis B (CHB) therapy is to achieve sustained suppression of HBV replication and remission of liver disease.Clinical CHB management guidelines suggest recommend threshold for antiviral therapy when ALT was more than 2 times ULN.No antiviral drugs are recommended for patients with normal ALT or mildly elevated ALT unless they exhibit symptoms of advanced fibrosis or liver cirrhosis.But chronic HBV infections with normal or mild ALT levels may develop latently into CHB,even cirrhosis and hepatocellular carcinoma (HCC).The ALT level is easily influenced by many factors.Antiviral therapy may still be needed for some HBV patients with normal or mildly abnormal ALT levels. Therefore, the investigator's purpose is to evaluate of antiviral indications and therapeutic effect by liver biopsy and clinical trial parameters on chronic HBV infection with different ALT levels,especially when ALT lower 2 times upper limit of normal (ULN).
Interventions
None listed
Sponsors
Yan'an University Affiliated Hospital
First Affiliated Hospital Xi'an Jiaotong University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
All of below 1. Patients with chronic HBV infection,defined as those in whom presence of serum hepatitis B surface(HBsAg) for more than 6 months; 2. All patients had underwent a liver biopsy; 3. All patients signed the informed consent before liver biopsy; 4. No history use of interferon or Nucleoside analogue treatment.
Exclusion criteria
Any of below 1. Co-infection with hepatitis A virus(HAV),hepatitis C virus(HCV),hepatitis D virus(HDV) hepatitis E virus(HEV) and/or human immunodeficiency virus(HIV); 2. Decompensated cirrhosis; 3. History of hepatocellular carcinoma(HCC); 4. History of liver transplantation; 5. Patient with a history of antiviral treatment; 6. Patient has medical condition that requires concurrent use of systemic prednisolone or other immunosuppressive agent (including chemotherapeutic agent) 7. Patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis,alpha-1 antitrypsin deficiency, Wilson's Disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease, etc.) 8. Patient who interrupted antiviral therapy; 9. Patient with incomplete data; 10. Follow up less than 1 year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Virological response in patients with different ALT levels | at 1 year | Serum HBV DNA will be summarized and compared between different groups at baseline and follow-up endpoint |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in serum HBsAg, HBeAg ,HBeAb ,HBcAb levels between treated and untreated groups | at baseline and 1 year | — |
| Proportion of patients with normal alanine aminotransferase(ALT) between treated and untreated groups | at baseline and 1 year | — |
| Liver stiffness measurement(LSM) changes between treated and untreated groups | at baseline and 1 year | LSM response is defined as LSM decrease at least a 1-kilopascal |
| Proportion of patients with HBsAg loss or seroconversion | at 1 year | — |
| (5) Predictive values of HBV DNA,HBsAg and LSM for the antiviral indications of chronic HBV infection with different ALT levels | at baseline | — |
Countries
China
Outcome results
None listed